713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL

Phase 3 ◽

Prior Chemotherapy ◽

97 Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy

European Urology Supplements ◽

10.1016/s1569-9056(13)60589-8 ◽

2013 ◽

Vol 12 (1) ◽

pp. e97-e98

Author(s):

H. Van Poppel ◽

D. Rathkopf ◽

M.R. Smith ◽

J.S. De Bono ◽

C.J. Logothetis ◽

...

Keyword(s):

Prostate Cancer ◽

Interim Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Prior Chemotherapy ◽

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

European Urology ◽

10.1016/j.eururo.2014.02.056 ◽

2014 ◽

Vol 66 (5) ◽

pp. 815-825 ◽

Cited By ~ 150

Author(s):

Dana E. Rathkopf ◽

Matthew R. Smith ◽

Johann S. de Bono ◽

Christopher J. Logothetis ◽

Neal D. Shore ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Abiraterone Acetate ◽

Prior Chemotherapy ◽

Efficacy Analysis ◽

Final Overall Survival (Os) Analysis of Cou-Aa-302, a Randomized Phase 3 Study of Abiraterone Acetate (Aa) in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts) Without Prior Chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdu336.1 ◽

2014 ◽

Vol 25 ◽

pp. iv255 ◽

Cited By ~ 23

Author(s):

C.J. Ryan ◽

M.R. Smith ◽

K. Fizazi ◽

K. Miller ◽

P. Mulders ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Abiraterone Acetate ◽

Phase 3 ◽

Prior Chemotherapy ◽

MP87-11 INTERIM ANALYSIS OF AN OPEN LABEL PHASE II STUDY OF ENZALUTAMIDE AND RADIUM RA 233 DICHLORIDE IN SYMPTOMATIC, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS.

The Journal of Urology ◽

10.1016/j.juro.2018.02.2911 ◽

2018 ◽

Vol 199 (4S) ◽

Author(s):

Neal Shore ◽

Paul Schellhammer ◽

Ronald Tutrone ◽

Neil Mariados ◽

Stacey Harrelson

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Study ◽

Open Label ◽

Castration Resistant ◽

Open Label Phase

Era 223—A Phase 3 Trial of Radium-223 Dichloride (Ra-223) in Combination with Abiraterone Acetate (Aa) and Prednisone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (Crpc)

Annals of Oncology ◽

10.1093/annonc/mdu336.50 ◽

2014 ◽

Vol 25 ◽

pp. iv278 ◽

Cited By ~ 1

Author(s):

M.R. Smith ◽

C. Parker ◽

B. Tombal ◽

K. Miller ◽

F. Saad ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Phase 3 ◽

Castration Resistant ◽

Radium 223

Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients

European Urology Oncology ◽

10.1016/j.euo.2019.01.008 ◽

2020 ◽

Vol 3 (1) ◽

pp. 119-127 ◽

Cited By ~ 2

Author(s):

Eleni Efstathiou ◽

Mark Titus ◽

Sijin Wen ◽

Patricia Troncoso ◽

Anh Hoang ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Abiraterone Acetate ◽

649P Abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy: A double-arm, multiple-centre, phase III clinical study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.908 ◽

2020 ◽

Vol 31 ◽

pp. S530

Author(s):

Z. Hu ◽

Z. Ye ◽

H. Zeng ◽

Y. Huang ◽

D. Ye ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Study ◽

Abiraterone Acetate ◽

Phase Iii ◽

Prior Chemotherapy ◽

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(12)70379-0 ◽

2012 ◽

Vol 13 (10) ◽

pp. 983-992 ◽

Cited By ~ 773

Author(s):

Karim Fizazi ◽

Howard I Scher ◽

Arturo Molina ◽

Christopher J Logothetis ◽

Kim N Chi ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Overall Survival Analysis

Budget Impact Analysis of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated with Docetaxel from the Perspective of the Brazilian Private Health Care System

Value in Health ◽

10.1016/j.jval.2013.08.1908 ◽

2013 ◽

Vol 16 (7) ◽

pp. A665 ◽

Cited By ~ 1

Author(s):

V. Vitale ◽

E. Asano ◽

M.L. Pereira

Keyword(s):

Prostate Cancer ◽

Health Care ◽

Cancer Patients ◽

Impact Analysis ◽

Budget Impact ◽

Abiraterone Acetate ◽

Private Health Care ◽

Castration Resistant ◽

Previously Treated

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel

Frontiers in Pharmacology ◽

10.3389/fphar.2017.00836 ◽

2017 ◽

Vol 8 ◽

Author(s):

Jian-Ri Li ◽

Kun-Yuan Chiu ◽

Shian-Shiang Wang ◽

Cheng-Kuang Yang ◽

Chuan-Shu Chen ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Abiraterone Acetate ◽

Combined Androgen Blockade ◽

Castration Resistant ◽

Androgen Blockade